Age-related macular degeneration market to reach $22.8 billion in 2031

The age-related macular degeneration (AMD) market in the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow from $7.3 billion in 2021 to $22.8 billion in 2031, driven by the longer-acting anti-vascular endothelial growth factor (VEGF) pipeline therapies as well as potentially first-to-market therapies for geographic atrophy (GA), forecasts data and analytics company GlobalData.

According to GlobalData, the growth will be supported by the US Food and Drug Administration (FDA) approval of Roche’s (ROG: SIX) Vabysmo (faricimab) for wet AMD (wAMD) in January 2022, coupled with the anticipated approval of longer-acting VEGF pipeline therapies as well as potentially first-to-market therapies for GA during the forecast period.

GlobalData’s latest report,  ‘Age-Related Macular Degeneration Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031’, reveals that anti-VEGF therapies will continue to remain the dominant treatment modality for wAMD during the forecast period. This theme is observed both in current marketed products as well as in pipeline products that are currently in late-stage development for wAMD, with companies focusing on reducing the treatment burden associated with these therapies.